Compare Huntington Ingalls Industries Inc (HII) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Johnson & Johnson — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 59.2× Huntington Ingalls Industries Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Johnson & Johnson for 129 Days on average.
| HII | JNJ | |
|---|---|---|
Market Cap | $10.44B | $618.09B |
Volume | 440,462 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $453.73 | $278.43 |
52-Week Low | $257.05 | $186.00 |
Typical Hold Time | 28 Days | 129 Days |
Enterprise Value | $13.37B | $646.37B |
Dividend Yield | 2.08% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.80, up 1.58% today, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 15.78, net income margin of 5.01%, and a $57.3 billion backlog supporting revenue visibility. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, highlight operational momentum amid consistent earnings beats.
The outlook is supported by strong defense budgets and execution, but risks include project delays and macroeconomic pressures. Analysts are generally positive with a $363.67 consensus target, implying significant upside, though technical indicators suggest near-term caution.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
